The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs. The Company operates in two segments: The services business and the co-development business. The clinical development services offered by the Company include study management, site management, study physician support, safety services, regulatory and quality management, clinical data management and biostatistics, and medical writing. It has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies, tri-functional antibodies, soluble receptors, cancer vaccines and immunotherapy, radioactive agents, and photodynamic therapies. The Company also has co-development deals with other companies.
Type
Public
HQ
Guildford, GB
Size (employees)
150 (est)
Ergomed is headquartered in Guildford, GB
Report incorrect company information

Ergomed Office Locations

Ergomed has an office in Guildford
Guildford, GB (HQ)
26 Frederick Sanger Rd
Show all (1)
Report incorrect company information

Ergomed Financials and Metrics

Ergomed Financials

Ergomed's revenue was reported to be £39.23 m in FY, 2016 which is a 30% increase from the previous period.
GBP

Revenue (FY, 2016)

39.2 m

Revenue growth (FY, 2015 - FY, 2016), %

30%

Gross profit (FY, 2016)

12 m

Gross profit margin (FY, 2016), %

30.6%

Net income (FY, 2016)

479 k

EBITDA (FY, 2016)

854 k

EBIT (FY, 2016)

598 k

Market capitalization (31-Oct-2017)

85.1 m

Closing share price (31-Oct-2017)

2.1

Cash (31-Dec-2016)

4.4 m

EV

80.7 m
Ergomed's current market capitalization is £85.1 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

7 m8.1 m9.6 m9.9 m12.1 m14.6 m15.1 m21.2 m30.2 m39.2 m

Revenue growth, %

40%43%30%

Cost of goods sold

5.7 m6 m6.4 m6.9 m8.1 m10.7 m10.1 m15.4 m21.8 m27.2 m

Gross profit

1.3 m2.1 m3.2 m3 m4 m3.9 m5 m5.8 m8.4 m12 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

452.5 k692.3 k467.9 k1 m642.2 k445 k2 m4.6 m4 m4.4 m

Accounts Receivable

1.8 m860.5 k2.1 m1.3 m3.1 m2.3 m2.3 m4.7 m6.4 m9.5 m

Current Assets

3.1 m1.9 m3.1 m2.9 m4.4 m4 m5.2 m10.9 m13.5 m19.8 m

PP&E

17 k476.1 k158.8 k175.7 k154.5 k164 k148 k185 k335 k717 k
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

343.8 k(39.7 k)124.5 k209.9 k534.7 k391 k1.5 m578 k1.6 m479 k

Cash From Operating Activities

191.7 k334.4 k(339.2 k)969 k(361.9 k)581 k1.4 m537 k264 k(2.4 m)

Dividends Paid

200 k180 k800 k

Cash From Financing Activities

(36.1 k)(99.4 k)(351.7 k)(15.9 k)(710 k)(68 k)9.1 m(1 k)8.7 m
GBPY, 2016

EV/EBITDA

94.5 x

EV/EBIT

134.9 x

EV/CFO

-34 x

Financial Leverage

1.6 x
Show all financial metrics

Ergomed Operating Metrics

Ergomed's Customers was reported to be 100 in FY, 2015.
FY, 2015

Countries

54

Customers

100

Patients Studied

30 k
Show all operating metrics
Report incorrect company information

Ergomed News and Updates

City Moves for 18 December 2017 - who's switching jobs?

Today's City Moves cover investing, equities research and pharma. Take a look at these movers and shakers: Burford Capital Elizabeth O’Connell has been appointed as Burford’s chief financial officer. Elizabeth has been a Burford managing director since its inception in 2009, managing its inves…

City Moves - who's switching jobs?

Today's City Moves cover investments,finance and advisory and pharmaceuticals. Take a look at these movers and shakers: Chartered Institute for Securities & Investment Edward Loader has been appointed president of the Chartered Institute for Securities & Investment (CISI) Jersey branch…
Report incorrect company information